In this context, retinal imaging, especially when coupled to a tau protein-sensitive fluorescent marker, is expected to revolutionize clinical trials on novel pharma products and become a routine for the screening even for asymptomatic, early-stage, AD, and FTD patients. This evidence concerns the gene MAPT and Alzheimer disease.